{"doi":"10.1093/noajnl/vdac067","title":"IDH-mutant astrocytoma with EGFR amplification—Genomic profiling in four cases and review of literature","abstract":"Abstract EGFR amplification is associated with aggressive glioma behavior and regarded as a molecular feature of glioblastoma. Although rare, IDH-mutant astrocytomas with EGFR amplification exist but remain poorly understood. We report the clinical and molecular profile of four grade 4 IDH-mutant astrocytomas with EGFR amplification, evaluated using histology, DNA sequencing, cytogenetics, and DNA methylation profiling. Other alterations included ATRX, TP53, and PIK3CA mutations; CDKN2A/B loss; PDGFRA+KIT amplifications; and MGMT methylation in two cases. None disclosed microsatellite instability. DNA methylation confidently classified all tumors as “IDH-mutant High-Grade Astrocytoma” (0.99 0.997, 0.98, and 0.99 scores), despite their EGFR-amplified status. Literature review indicated EGFR amplification occurs within 8-19% of IDH-mutant gliomas, with significantly lower overall survival only in the co-presence of CDKN2A/B loss and MET amplification. Our report suggests IDH-mutant astrocytomas with EGFR amplification are under-recognized and that EGFR amplification status alone does not carry diagnostic or prognostic significance in these tumors.","journal":"Neuro-Oncology Advances","year":2022,"id":258663,"datarank":0.0,"base_score":0.0,"endowment":0.0,"self_citation_contribution":0.0,"citation_network_contribution":0.0,"self_endowment_contribution":0.0,"citer_contribution":0.0,"corpus_percentile":null,"corpus_rank":null,"citation_count":17,"citer_count":0,"citers_with_citation_signal":0,"citers_with_endowment":0,"datacite_reuse_total":0,"is_dataset":false,"is_dataset_confidence":0.9486,"is_data_producer":false,"deposit_databanks":null,"is_oa":true,"file_count":0,"downloads":0,"has_version_chain":false,"published_date":"2022-01-01","fair_score":null,"fair_percentile":null,"algorithm_id":"datarank_citation_only_1hop_v6","ranking_scope":"data_only","authors":[{"id":55987,"name":"Khawaja Hasan Bilal","orcid":null,"position":1,"is_corresponding":false},{"id":910233,"name":"Michael L. Martini","orcid":"0000-0001-8169-7679","position":2,"is_corresponding":false},{"id":635890,"name":"Abigail K. Suwala","orcid":"0009-0003-8394-1905","position":3,"is_corresponding":false},{"id":635272,"name":"Sadhna Ahuja","orcid":null,"position":4,"is_corresponding":false},{"id":1997,"name":"Omid Rashidipour","orcid":"0000-0002-1156-1730","position":5,"is_corresponding":false},{"id":910234,"name":"Isabelle M. Germano","orcid":"0000-0002-3992-373X","position":6,"is_corresponding":false},{"id":236056,"name":"Matija Snuderl","orcid":"0000-0003-0752-0917","position":7,"is_corresponding":false},{"id":302623,"name":"Peter Morgenstern","orcid":"0000-0002-2409-3614","position":8,"is_corresponding":false},{"id":2003,"name":"Nadejda M. Tsankova","orcid":"0000-0002-5333-312X","position":9,"is_corresponding":false},{"id":910742,"name":"Melissa Umphlett","orcid":null,"position":0,"is_corresponding":true}],"reference_count":16,"raw_metadata":null,"created_at":"2026-07-19T00:25:43.037820Z","pmid":"35669011","pmcid":null,"fwci":null,"citation_percentile":null,"influential_citations":0,"oa_status":null,"license":null,"views":0,"total_file_size_bytes":0,"version_count":0,"fair_f":null,"fair_a":null,"fair_i":null,"fair_r":null,"fair_zscore":null,"fair_rationale":null,"fair_model":null,"fair_agent_version":null,"fair_fulltext_source":null,"fair_has_llm":null,"fair_computed_at":null,"clinical_trials":[],"software_tools":[],"db_accessions":[],"linked_datasets":[],"topics":[]}